Nevirapine
NDC Package 53808-1069-1

11-digit billing NDC: 53808106901

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Nevirapine is indicated for combination antiretroviral treatment of HIV-1 infection in adults and in pediatrics patients 15 days and older [see Clinical Studies (14.1), (14.2)].Additional important information regarding the use of nevirapine for the treatment of HIV-1 infection:•Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see Boxed Warning and Warnings and Precautions (5.1)].•The 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].•If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought. Marketed by State Of Florida Doh Central Pharmacy, this product is identified by NDC 53808-1069 and is authorized under FDA application ANDA203176.

Identification & Billing

NDC Package Code
53808-1069-1
Package Description
30 TABLET in 1 BLISTER PACK
Product Code
11-Digit Billing Format
53808106901
RxNorm Crosswalk
RxCUI: 199422 - nevirapine 200 MG Oral Tablet

Clinical Specifications

Proprietary Name
Nevirapine
Dosage Form
-
Usage Information
Nevirapine is indicated for combination antiretroviral treatment of HIV-1 infection in adults and in pediatrics patients 15 days and older [see Clinical Studies (14.1), (14.2)].Additional important information regarding the use of nevirapine for the treatment of HIV-1 infection:•Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk [see Boxed Warning and Warnings and Precautions (5.1)].•The 14-day lead-in period with nevirapine 200 mg daily dosing must be strictly followed; it has been demonstrated to reduce the frequency of rash [see Dosage and Administration (2.4) and Warnings and Precautions (5.2)].•If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought.

Regulatory & Marketing

Labeler Name
State Of Florida Doh Central Pharmacy
FDA Application #
ANDA203176
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
11-01-2014
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 53808-1069-1 identifies a specific commercial package of 30 tablet in 1 blister pack of Nevirapine, labeled by State Of Florida Doh Central Pharmacy. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by State Of Florida Doh Central Pharmacy on November 01, 2014. The current certification is valid through December 31, 2017.

How is this State Of Florida Doh Central Pharmacy product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 53808106901. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
53808-1069-1
11-Digit CMS (5-4-2)
53808-1069-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.